Blog
RSS FeedPosted by Michael Wonder on 04 Feb 2025
Durvalumab with tremelimumab for the first-line treatment of patients with advanced or unresectable hepatocellular carcinoma
4 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 22 Jan 2025
Abiraterone acetate with niraparib tosylate monohydrate and prednisone for untreated hormone-relapsed metastatic prostate cancer
22 January 2025 - NICE is unable to make a recommendation on the use in the NHS of abiraterone acetate with ...
Posted by Michael Wonder on 21 Jan 2025
NICE has made six times more lung cancer treatment recommendations over the past ten years than in the previous decade
21 January 2025 - We have also recommended osimertinib for routine use on the NHS today. ...
Posted by Michael Wonder on 15 Jan 2025
Capivasertib in combination with fulvestrant for the treatment of patients with advanced, hormone receptor positive, HER2 negative breast cancer after endocrine treatment
14 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 10 Jan 2025
Erdafitinib for the treatment of patients with metastatic or unresectable FGFR altered urothelial cancer
9 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Dec 2024
Over 1,000 people with advanced breast cancer set to benefit from new once a day tablet
19 December 2024 - We’ve issued final draft guidance recommending a new once a day tablet that is set to benefit ...
Posted by Michael Wonder on 12 Dec 2024
Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced oesophageal squamous cell cancer
11 December 2024 - NICE is unable to make a recommendation on the use in the NHS of toripalimab (Loqtorzi) in ...
Posted by Michael Wonder on 12 Dec 2024
Elranatamab for treating relapsed and refractory multiple myeloma after three or more treatments (final guidance)
11 December 2024 - NICE has published final evidence-based recommendations on the use of elranatamab (Elrexfio) for the treatment of ...
Posted by Michael Wonder on 30 Nov 2024
NICE responds to failure of talks to reach price agreement on Enhertu
19 November 2024 - Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu ...
Posted by Michael Wonder on 14 Nov 2024
Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (final guidance)
13 November 2024 - NICE has published final evidence-based recommendations on the use of teclistamab (Tecvayli) for the treatment of ...
Posted by Michael Wonder on 13 Nov 2024
Sanofi wins appeal in spat with NICE over Sarclisa
13 November 2024 - Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS ...
Posted by Michael Wonder on 13 Nov 2024
Alectinib hydrochloride for the adjuvant treatment of patients with ALK positive non-small-cell lung cancer
13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment ...
Posted by Michael Wonder on 30 Oct 2024
Osimertinib mesylate in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced EGFR mutation positive non-small-cell lung cancer
30 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Oct 2024
People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy
29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE ...
Posted by Michael Wonder on 24 Oct 2024
Quizartinib dihydrochloride for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, ...